search
Back to results

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Primary Purpose

Carcinoma

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Paclitaxel
Carboplatin
Bevacizumab
Erlotinib
Treatment determined by physician
Sponsored by
SCRI Development Innovations, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carcinoma focused on measuring Carcinoma of Unknown Primary Site, Molecular profiling assay, Bevacizumab, Erlotinib, Paclitaxel, Carboplatin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients must have carcinoma of unknown primary site after the following diagnostic procedures have been performed and are unrevealing of a primary site:

    • Complete medical history and physical examination,
    • Complete blood counts, chemistry profile,
    • CT scans of the chest and abdomen,
    • Directed evaluation of any symptomatic areas,
    • PET scan (recommended).
  2. Patients must have biopsy-proven metastatic carcinoma, with any of the following light microscopic histologies:

    • Adenocarcinoma,
    • Poorly differentiated adenocarcinoma,
    • Poorly differentiated carcinoma (all patients with poorly differentiated carcinoma must have immunoperoxidase stains to rule out other treatable malignancies [e.g., lymphoma, neuroendocrine carcinoma]),
    • Poorly differentiated squamous carcinoma.
  3. Patients must have biopsy material available from a surgical biopsy, a core needle biopsy, or a fine needle aspiration biopsy to provide an adequate specimen (must be 40% tumor) for the molecular profiling assay.
  4. An ECOG performance status 0, 1, or 2.
  5. No previous treatment with any systemic therapy.
  6. Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST).
  7. Laboratory values as follows:

    • WBC 4000/micro L,
    • Platelets 100,000/micro L,
    • Serum bilirubin <1.5 times the institutional upper limits of normal (ULN),
    • Serum creatinine < 2.0 mg/dL.
  8. Patients with brain metastases are eligible only if all lesions have been controlled by surgical resection or radiation therapy, the patient is not steroid-dependent, and the patient meets all other eligibility criteria.
  9. Patients must be > 4 weeks from any major operative procedure.
  10. To be eligible for the TREATMENT portion of the study, patients must have one of the five following diagnoses: colorectal, pancreas, NSCLC, ovary, renal cancer.
  11. Patients must be able to understand the nature of this study and give written informed consent.

Exclusion Criteria:

  1. Patients with the following specific syndromes are not eligible:

    • Patients with neuroendocrine carcinoma,
    • Women with adenocarcinoma isolated to axillary lymph nodes,
    • Women with adenocarcinoma isolated to peritoneal involvement,
    • Patients with carcinoma involving only 1 site, with resectable tumor at that site, or
    • Patients with squamous carcinoma limited to cervical, supraclavicular, or inguinal lymph nodes.
  2. Patients with uncontrolled brain metastases and all patients with meningeal metastases.
  3. Patients with insufficient biopsy material available for molecular profiling assay.
  4. Women who are pregnant or lactating. All females of child-bearing potential must have a negative serum or urine pregnancy tests within 7 days prior to study treatment.
  5. Men and women of childbearing potential are required to use effective methods of contraception during this study and for 6 months after ending therapy.
  6. Patients who have received any other experimental drug within 28 days of starting treatment.

Exclusion Criteria for All Patients Receiving Bevacizumab-Containing Regimens

  1. Patients with history of acute myocardial infarction within 6 months, other clinically significant cardiovascular disease (e.g., unstable angina, New York Heart Association [NYHA] grade 2 congestive heart failure [CHF], serious cardiac arrhythmias requiring medication) or > grade 2 vascular disease.
  2. Patients with uncontrolled hypertension (systolic blood pressure [BP] 150 or diastolic BP >100mm Hg) or uncontrolled cardiac arrhythmias.
  3. Prior hypertensive crisis or hypertensive encephalopathy.
  4. Patients with clinical history of hemoptysis (defined as bright red blood of

    ½ teaspoon per episode) or hematemesis within 1 month prior to Day 1.

  5. Patients with PEG tubes or G tubes.
  6. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study.
  7. Core biopsy or other minor surgical procedure excluding placement of a vascular access device, within 7 days prior to Day 1.
  8. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1.
  9. Patients with proteinuria (1000 mg/24 hours) at screening will be excluded. A 24-hour urine collection is not required in all patients (e.g., patients whose treatment plans exclude bevacizumab); however, all patients receiving bevacizumab with 1+ proteinuria on dipstick urinalysis at study entry must have a subsequent 24-hour urine collection.
  10. Patients with any non-healing wound, ulcer, or long bone fracture.
  11. Patients with any history of a bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
  12. Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab.
  13. Patients with a history of stroke or transient ischemic attach within 6 months prior to first bevacizumab dose.
  14. Known hypersensitivity to any component of bevacizumab.
  15. Patients with history of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of a novel regimen, or that might affect the results of this study or render the subject at high risk for treatment complications.

Sites / Locations

  • Oncology Specialties (Clearview Cancer Institute)
  • Florida Cancer Specialists
  • Integrated Community Oncology Network
  • Watson Clinic Center for Cancer Care and Research
  • Florida Hospital Cancer Institute
  • Northeast Georgia Medical Center
  • Wellstar Cancer Research
  • Oncology Hematology Associates of SW Indiana
  • Baptist Hospital East
  • Hematology Oncology Clinic, LLP
  • Center for Cancer and Blood Disorders
  • Grand Rapids Clinical Oncology Program
  • Jackson Oncology Associates
  • Nebraska Methodist Cancer Center
  • Hematology Oncology Associates of Northern NJ
  • Oncology Hematology Care
  • Spartanburg Regional Medical Center
  • Chattanooga Oncology Hematology Associates
  • Tennessee Oncology, PLLC
  • Center for Cancer and Blood Disorders
  • Virginia Cancer Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Paclitaxel, Carboplatin, Bevacizumab and Erlotinib

Treatment determined by physician

Arm Description

Paclitaxel, Carboplatin, Bevacizumab and Erlotinib

Other treatment determined by physician based on molecular profiling assay

Outcomes

Primary Outcome Measures

Overall Survival
Defined as the elapsed time from the start of treatment to the date of death from any cause or lost to follow-up. Participants lost to follow up were censored as of the last date known to be alive.

Secondary Outcome Measures

Number of Participants With a Tissue of Origin Successfully Predicted by the Assay
To evaluate the utility of the assay in identifying the tissue of origin in patients with carcinoma of unknown primary site (CUP), an archived tumor specimen was assayed upon study entry. If a tissue of origin was predicted by the assay, participants received standard site-specific therapy for that tumor type. When tissue of origin was not predicted by the assay, patients received standard empiric chemotherapy for CUP and were not followed further. If the assay was not completed due to inadequate amount of tumor in the biopsy specimen, patients were not treated on the study.

Full Information

First Posted
August 15, 2008
Last Updated
July 7, 2016
Sponsor
SCRI Development Innovations, LLC
Collaborators
Genentech, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00737243
Brief Title
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Official Title
A Phase II Study of Chemotherapy Treatment Based on Molecular Profiling Diagnosis for Patients With Carcinoma of Unknown Primary Site
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
December 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SCRI Development Innovations, LLC
Collaborators
Genentech, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a non-randomized Phase II study. Patients determined at initial diagnosis to have a carcinoma of unknown primary site (CUP) will have their treatment selected with the use of a molecular profiling assay. The assay will be performed on paraffin-embedded tumor tissue from a biopsy specimen. Patients given specific diagnoses (e.g., lung, pancreas, colon, breast, renal cell, prostate and ovarian cancer) will receive treatment regimens of proven activity. If no specific diagnosis is made with the molecular profiling assay, empiric chemotherapy with paclitaxel, carboplatin, bevacizumab and erlotinib will be administered.
Detailed Description
The primary objective of the study is evaluate the impact of the molecular assay prediction on the efficacy of therapy for patients with carcinoma of unknown primary site (CUP). Investigators will use tumor profiling results to direct standard, site-specific first-line therapy for patients with CUP.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carcinoma
Keywords
Carcinoma of Unknown Primary Site, Molecular profiling assay, Bevacizumab, Erlotinib, Paclitaxel, Carboplatin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
289 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
Arm Type
Experimental
Arm Description
Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
Arm Title
Treatment determined by physician
Arm Type
Other
Arm Description
Other treatment determined by physician based on molecular profiling assay
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
175 mg/m2, 1-3 hour IV infusion Day 1
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
AUC 6.0 IV Day 1
Intervention Type
Drug
Intervention Name(s)
Bevacizumab
Other Intervention Name(s)
Avastin
Intervention Description
15 mg/kg IV infusion Day 1
Intervention Type
Drug
Intervention Name(s)
Erlotinib
Other Intervention Name(s)
Tarceva
Intervention Description
150 mg PO
Intervention Type
Other
Intervention Name(s)
Treatment determined by physician
Intervention Description
Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
Primary Outcome Measure Information:
Title
Overall Survival
Description
Defined as the elapsed time from the start of treatment to the date of death from any cause or lost to follow-up. Participants lost to follow up were censored as of the last date known to be alive.
Time Frame
every 6-8 weeks (2 cycles) until death from any cause or lost to follow up, projected 18 months
Secondary Outcome Measure Information:
Title
Number of Participants With a Tissue of Origin Successfully Predicted by the Assay
Description
To evaluate the utility of the assay in identifying the tissue of origin in patients with carcinoma of unknown primary site (CUP), an archived tumor specimen was assayed upon study entry. If a tissue of origin was predicted by the assay, participants received standard site-specific therapy for that tumor type. When tissue of origin was not predicted by the assay, patients received standard empiric chemotherapy for CUP and were not followed further. If the assay was not completed due to inadequate amount of tumor in the biopsy specimen, patients were not treated on the study.
Time Frame
at baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must have carcinoma of unknown primary site after the following diagnostic procedures have been performed and are unrevealing of a primary site: Complete medical history and physical examination, Complete blood counts, chemistry profile, CT scans of the chest and abdomen, Directed evaluation of any symptomatic areas, PET scan (recommended). Patients must have biopsy-proven metastatic carcinoma, with any of the following light microscopic histologies: Adenocarcinoma, Poorly differentiated adenocarcinoma, Poorly differentiated carcinoma (all patients with poorly differentiated carcinoma must have immunoperoxidase stains to rule out other treatable malignancies [e.g., lymphoma, neuroendocrine carcinoma]), Poorly differentiated squamous carcinoma. Patients must have biopsy material available from a surgical biopsy, a core needle biopsy, or a fine needle aspiration biopsy to provide an adequate specimen (must be 40% tumor) for the molecular profiling assay. An ECOG performance status 0, 1, or 2. No previous treatment with any systemic therapy. Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST). Laboratory values as follows: WBC 4000/micro L, Platelets 100,000/micro L, Serum bilirubin <1.5 times the institutional upper limits of normal (ULN), Serum creatinine < 2.0 mg/dL. Patients with brain metastases are eligible only if all lesions have been controlled by surgical resection or radiation therapy, the patient is not steroid-dependent, and the patient meets all other eligibility criteria. Patients must be > 4 weeks from any major operative procedure. To be eligible for the TREATMENT portion of the study, patients must have one of the five following diagnoses: colorectal, pancreas, NSCLC, ovary, renal cancer. Patients must be able to understand the nature of this study and give written informed consent. Exclusion Criteria: Patients with the following specific syndromes are not eligible: Patients with neuroendocrine carcinoma, Women with adenocarcinoma isolated to axillary lymph nodes, Women with adenocarcinoma isolated to peritoneal involvement, Patients with carcinoma involving only 1 site, with resectable tumor at that site, or Patients with squamous carcinoma limited to cervical, supraclavicular, or inguinal lymph nodes. Patients with uncontrolled brain metastases and all patients with meningeal metastases. Patients with insufficient biopsy material available for molecular profiling assay. Women who are pregnant or lactating. All females of child-bearing potential must have a negative serum or urine pregnancy tests within 7 days prior to study treatment. Men and women of childbearing potential are required to use effective methods of contraception during this study and for 6 months after ending therapy. Patients who have received any other experimental drug within 28 days of starting treatment. Exclusion Criteria for All Patients Receiving Bevacizumab-Containing Regimens Patients with history of acute myocardial infarction within 6 months, other clinically significant cardiovascular disease (e.g., unstable angina, New York Heart Association [NYHA] grade 2 congestive heart failure [CHF], serious cardiac arrhythmias requiring medication) or > grade 2 vascular disease. Patients with uncontrolled hypertension (systolic blood pressure [BP] 150 or diastolic BP >100mm Hg) or uncontrolled cardiac arrhythmias. Prior hypertensive crisis or hypertensive encephalopathy. Patients with clinical history of hemoptysis (defined as bright red blood of ½ teaspoon per episode) or hematemesis within 1 month prior to Day 1. Patients with PEG tubes or G tubes. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study. Core biopsy or other minor surgical procedure excluding placement of a vascular access device, within 7 days prior to Day 1. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1. Patients with proteinuria (1000 mg/24 hours) at screening will be excluded. A 24-hour urine collection is not required in all patients (e.g., patients whose treatment plans exclude bevacizumab); however, all patients receiving bevacizumab with 1+ proteinuria on dipstick urinalysis at study entry must have a subsequent 24-hour urine collection. Patients with any non-healing wound, ulcer, or long bone fracture. Patients with any history of a bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation). Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab. Patients with a history of stroke or transient ischemic attach within 6 months prior to first bevacizumab dose. Known hypersensitivity to any component of bevacizumab. Patients with history of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of a novel regimen, or that might affect the results of this study or render the subject at high risk for treatment complications.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John D Hainsworth, M.D.
Organizational Affiliation
SCRI Development Innovations, LLC
Official's Role
Study Chair
Facility Information:
Facility Name
Oncology Specialties (Clearview Cancer Institute)
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35805
Country
United States
Facility Name
Florida Cancer Specialists
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33901
Country
United States
Facility Name
Integrated Community Oncology Network
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256
Country
United States
Facility Name
Watson Clinic Center for Cancer Care and Research
City
Lakeland
State/Province
Florida
ZIP/Postal Code
33805
Country
United States
Facility Name
Florida Hospital Cancer Institute
City
Orlando
State/Province
Florida
ZIP/Postal Code
32804
Country
United States
Facility Name
Northeast Georgia Medical Center
City
Gainesville
State/Province
Georgia
ZIP/Postal Code
30501
Country
United States
Facility Name
Wellstar Cancer Research
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
Oncology Hematology Associates of SW Indiana
City
Evansville
State/Province
Indiana
ZIP/Postal Code
47714
Country
United States
Facility Name
Baptist Hospital East
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Facility Name
Hematology Oncology Clinic, LLP
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70809
Country
United States
Facility Name
Center for Cancer and Blood Disorders
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20817
Country
United States
Facility Name
Grand Rapids Clinical Oncology Program
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49503
Country
United States
Facility Name
Jackson Oncology Associates
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39202
Country
United States
Facility Name
Nebraska Methodist Cancer Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68114
Country
United States
Facility Name
Hematology Oncology Associates of Northern NJ
City
Morristown
State/Province
New Jersey
ZIP/Postal Code
07960
Country
United States
Facility Name
Oncology Hematology Care
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Facility Name
Spartanburg Regional Medical Center
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29303
Country
United States
Facility Name
Chattanooga Oncology Hematology Associates
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
Facility Name
Tennessee Oncology, PLLC
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37023
Country
United States
Facility Name
Center for Cancer and Blood Disorders
City
Ft. Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Facility Name
Virginia Cancer Institute
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23235
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
23032625
Citation
Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013 Jan 10;31(2):217-23. doi: 10.1200/JCO.2012.43.3755. Epub 2012 Oct 1.
Results Reference
derived

Learn more about this trial

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

We'll reach out to this number within 24 hrs